No products in the cart.
Reports & Databases
Subscribe to
our newsletters!
Showing 41–54 of 54 results
- February of 2019This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.€ 100.00
- May of 2018These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.€ 2670.00
- January of 2019This report informs about the competitive field of novel DNA vaccines in clinical development for prevention and/or treatment of cancer, infectious and other diseases.€ 400.00
- January of 2019This Target Pipeline List provides an overview of biologic and small molecule approaches to raise high density lipoprotein (HDL) for reduction of recurrent cardiovascular events.€ 100.00
- December of 2018This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.€ 75.00
- May of 2018This report brings you up-to-date regarding key TCR-T players, technologies and product candidates, business models, deals and funding opportunities and analyzes the TCR-T pipelines and stakeholders in the field.€ 2150.00
- January of 2018This report informs you about key technologies to identify and validate intracellular targets, to generate TCRs and TCR fusion proteins, to discover TCR-like antibodies, and construct cell-penetrating peptides, proteins and...€ 2000.00
- November of 2018This R&D Drug Pipeline Database provides 24/7 online access to information from more than 23,400 files of therapeutic drugs on the market and of investigational drug candidates in R&D.€ 6000.00
- January of 2019This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.€ 100.00
- January of 2019This Target Pipeline list provides an overview of antibody- and cell-based therapeutics targeting DLL3 in development for treatment of DLL3-overexpressing cancers.€ 50.00
- January of 2019This Target Pipeline List provides a pipeline overview of tau imaging agents in development for diagnosis of tauopathies and measurement of tau-targeted treatment effects€ 50.00
- January of 2019This Target Pipeline List provides a pipeline overview of EP4 receptor antagonists in development for treatment of cancer€ 50.00
- November of 2020Information about R&D projects is identified and retrieved from company publications including, but not limited to, press releases, presentations, website disclosures, SEC publications, regulatory documents, scientific abstracts and full papers,...€ 1500.00
